New DEP drug delivery program initiated with AstraZeneca
Filed with ASX · · 2 pages · English
Starpharma Holdings Limited on 6ix
Story so far
Earlier from Starpharma
- Starpharma signs license for a VivaGel condom in China
- Appendix 4C - Quarterly Cashflow Reoprt
- Starpharmas DEP eliminates cabazitaxel neutropenia
- VivaGel active against Zika virus
- DEP cabazitaxel shows complete, sustained tumour regression
Later from Starpharma
- VivaGel condom receives regulatory approval in Canada
- Enrolment complete for Phase 3 VivaGel BV-R program
- Additional Priostar Glyphosate Patent Allowed in US
- Starpharma signs license for VivaGel Condom in Iran
- Starpharma receives $3.5M R&D tax incentive refund
Follow Starpharma into a list and get an email when it puts out news.
Follow Starpharma